High expression of crystallin αb represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells

International Journal of Cancer

Volumn 132, Issue 12, 2013, Pages 2820-2832

  Volkmann, Juliane ^a   Reuning, Ute ^a   Rudelius, Martina ^b   Häfner, Norman ^c   Schuster, Tibor ^a   V Rose, Aaron Becker ^a   Weimer, Joerg ^d   Hilpert, Felix ^d   Kiechle, Marion ^a   Dürst, Matthias ^c   Arnold, Norbert ^d   Schmalfeldt, Barbara ^a   Meindl, Alfons ^a   Ramser, Juliane ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

apoptosis; CRYAB; ovarian cancer; survival predicting marker; TRAIL

Indexed keywords

ALPHA CRYSTALLIN; CASPASE 3; CISPLATIN; KILLERTRAIL; MESSENGER RNA; PACLITAXEL; PLATINUM COMPLEX; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALPHA CRYSTALLIN GENE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA HYBRIDIZATION; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STABLE TRANSFECTION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-CRYSTALLIN B CHAIN; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; ENZYME ACTIVATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL;

EID: 84876154358     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27975     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. International Agency for Research on Cancer (IARC) (http://www.iarc.fr/).
3. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1: S161-92.
4. Agarwal R, Kaye SB,. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-16.
5. Pennington K, Pulaski H, Pennington M, et al. Too much of a good thing: suicide prevention promotes chemoresistance in ovarian carcinoma. Curr Cancer Drug Targets 2010; 10: 575-83.
6. Duiker EW, Meijer A, van der Bilt AR, et al. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer 2011; 104: 1278-87.
7. Mao YW, Liu JP, Xiang H, et al. Human αA- and αB-crystallins bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine-induced apoptosis. Cell Death Differ 2004; 11: 512-26.
8. Liu S, Li J, Tao Y, Xiao X,. Small heat shock protein αB-crystallin binds to p53 to sequester its translocation to mitochondria during hydrogen peroxide-induced apoptosis. Biochem Biophys Res Commun 2007; 354: 109-14.
9. Kamradt MC, Chen F,;, Cryns VL,. The small heat shock protein αB-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 2001; 276: 16059-63.
10. Kamradt MC, Chen F, Sam S, et al. The small heat shock protein αB-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol Chem 2002; 277: 38731-36.
11. Kamradt MC, Lu M, Werner ME, et al. The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 2005; 280: 11059-66.
12. Bevis KS, Buchsbaum DJ, Straughn M,. Overcoming TRAIL resistance in ovarian carcinoma. Gynecol Oncol 2010; 119: 157-63.
13. Lancaster JM, Sayer R, Blanchette C, et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 2003; 9: 762-66.
14. Estes JM, Oliver PG, Straughn JM Jr, et al. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 2007; 105: 291-98.
15. Duiker EW, de Vries EG, Mahalingam D, et al. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 2009; 15: 2048-57.
16. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25: 1390-5.
17. Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 3450-5.
18. ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT00819169).
19. Farfsing A, Engel F, Seiffert M, et al. Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. Leukemia 2009; 23: 2018-26 (online supplementary information).
20. nd ed. New York: Springer, 2009. 242-249.
21. Gyorffy B, Lanczky A, Szallasi Z,. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012; 19: 197-208.
22. Loessner D, Abou-Ajram C, Benge A, et al. Integrin αvβ3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription. J Cell Physiol 2009; 220: 367-75.
23. Moebus V, Gerharz CD, Press U, et al. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 1992; 52: 76-84.
24. Hapke S, Kessler H, Luber B, et al. Ovarian cancer cell proliferation and motility is induced by engagement of integrin αvβ3/vitronectin interaction. Biol Chem 2003; 384: 1073-83.
25. Capes-Davis A, Theodosopoulos G, Atkin I, et al. Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer 2010; 127: 1-8.
26. Hapke S, Kessler H, Arroyo de Prada N, et al. Integrin αvβ3/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem 2001; 276: 26340-8.
27. Meinhold-Heerlein I, Borges-Engeby K, Grünn U, et al. Untersuchungen zur TRAIL-induzierten Apoptose von Ovarialkarzinomzelllinien mit selektiver Zytostatikaresistenz. Geburtsh Frauenheilk 2005; 65: 1064-73.
28. Dahl E, Sadr-Nabavi A, Klopocki E, et al. Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol 2005; 205: 21-8.
29. Moyano JV, Evans JR, Chen F, et al. αB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006; 116: 261-70.
30. Ivanov O, Chen F, Wiley EL, et al. αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2008; 111: 411-7.
31. Chin D, Boyle GM, Williams RM, et al. αB-crystallin, a new independent marker for poor prognosis in head and neck cancer. Laryngoscope 2005; 115: 1239-42.
32. Welsh MJ, Gaestel M,. Small heat-shock protein family: function in health and disease. Ann N Y Acad Sci 1998; 851: 28-35.
33. Newsom-Davis T, Prieske S, Walczak H,. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009; 14: 607-23.
34. Bellail AC, Qi L, Mulligan P, et al. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009; 4: 34-41.
35. Goncharenko-Khaider N, Lane D, Matte I, et al. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 2010; 29: 5523-36.
36. Lane D, Côté M, Grondin R, et al. Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol Cancer Ther 2006; 5: 509-21.
37. Lane D, Robert V, Grondin R, et al. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007; 121: 1227-37.
38. Lane D, Goncharenko-Khaider N, Rancourt C, et al. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010; 29: 3519-31.
39. Lane D, Matte I, Rancourt C, et al. The prosurvival activity of ascites against TRAIL is associated with shorter disease-free interval in patients with ovarian cancer. J Ovarian Res 2010; 3: 1-10.
40. Schaner ME, Davidson B, Skrede M, et al. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer 2005; 4: 26-40.